Fig. 1

The ACC MTB network. A Most frequently discussed neoplasms. Respondents were given the option to tick more than one in a series of multiple choices. B MTB staff members ranked by frequency. C Frequently appointed discussants. D Case-mix: MTBs assigning treatment both in indication (SoC) and off-label (blue), and off-label only (orange). E numerosity and case-mix: MTBs (n. 1–16) were ranked by the number of cases discussed per year (descending order; shades of blue). Each MTB is also pseudo-colored in shades of red (color intensity proportional to case-mix as defined in D). F Confidence in liquid biopsy. G Complexity (n. of genes) of clinical NGS panels used for tissue and blood. H Failure to administer MTB-recommended off-label treatment and causes thereof. I Funds to support off-label treatment (J) Top three international scales of actionable biomarkers (levels of evidence) adopted by the ACC MTB Workgroup